Alume Biosciences is awarded an SBIR grant from the National Institute of Health

[San Diego, CA][April 5, 2019]Alume Biosciences announced today that it is the recipient of an SBIR development grant from the National Institute of Health. The PI on this grant is Michael Whitney, PhD, Scientific Co-Founder and Vice President of Discovery at Alume. The SBIR program provides capital to early stage businesses creating innovative technologies for improving health. Program grants are awarded to companies with promising technologies that have a strong potential for commercialization, to help translate life-saving innovations to consumer markets and create jobs in biotechnology. Alume Biosciences will apply this grant funding towards its development of a nerve illumination agent for use during surgery.